Clinical trials
Pneumonia, Bacterial clinical trials
Below are recruiting pneumonia, bacterial clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07759934RecruitingPhase 2
Comparing ASK0912 to polymyxin B for hospital-acquired pneumonia
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
Nanjing, JiangsuAges 18 years+ - NCT07326540RecruitingPhase 3
Testing a new antibiotic for drug-resistant pneumonia in the hospital
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
TbilisiAges 18–82 - NCT06841731RecruitingPhase 2
Testing a new antibiotic for hospital-acquired pneumonia
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07004049RecruitingPhase 4
Testing combinations for resistant Gram-negative infections
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Brisbane, QueenslandAges 18 years+ - NCT06087536RecruitingPhase 2
Trial of OMN6 for hospital-acquired Acinetobacter pneumonia
This trial tests a new antibiotic called OMN6 for people with a serious lung infection (pneumonia) caught in the hospital or from a breathing machine, caused by a hard-to-treat bacteria (Acinetobacter). The goal is to see if OMN6 is safe and how the body processes it.
AshdodAges 18–99 - NCT07327619RecruitingPhase 3
Testing a New Antibiotic Combo for Hospital-Acquired Pneumonia
This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.
Huaihua, HunanAges 18–80 - NCT07089186RecruitingPhase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
ShanghaiAges 18–80 - NCT06670833Recruiting
Tools to improve childhood pneumonia care
This trial tests new tools to help doctors diagnose and manage pneumonia in children. It may help children with cough or trouble breathing who are not severely ill.
DakarAges 2 months–12 years - NCT07086391Recruiting
Inhaled Polymyxin B for Resistant Pneumonia
This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.
Fuzhou, FujianAges 18–90 - NCT05123755RecruitingPhase 2
Testing a new medicine in hospitalized pneumonia patients needing oxygen
This Phase 2 trial tests an investigational medicine (given in increasing doses) for hospitalized people with pneumonia who need supplemental oxygen. It aims to see if the medicine is safe and potentially helps the pneumonia process in the early hospital period.
Newport Beach, CaliforniaAges 18 years+ - NCT07492771RecruitingPhase 1
Study of MP101 for adults with Pseudomonas pneumonia
This trial tests an experimental treatment called MP101 for adults with pneumonia caused by the bacteria Pseudomonas aeruginosa (PA). It aims to help patients whose infection is not responding to current antibiotics.
Seoul, Seodaemun-guAges 19 years+ - NCT06238297Recruiting
Testing early stopping of MRSA antibiotics for pneumonia
This trial tests whether a simple nasal swab can help doctors safely stop unnecessary MRSA antibiotics sooner in people with pneumonia. If the swab shows no MRSA, the antibiotic can be stopped early, which may reduce side effects and drug resistance.
BariAges 18 years+ - NCT02979951Recruiting
IV fosfomycin for serious bacterial infections
This trial studies whether IV (through a vein) fosfomycin can treat severe bacterial infections in adults. It may help people whose infection is covered by the standard fosfomycin use and who need hospital-level care.
Hall in TirolAges 18 years+ - NCT07113951Enrolling by invitation
AI-ROSE for diagnosing severe pneumonia
This trial uses an AI tool called AI-ROSE to analyze lung fluid from a bronchoscopy. It aims to help doctors quickly diagnose severe pneumonia and guide treatment.
Nanjing, JiangsuAges 18 years+ - NCT04178915Enrolling by invitation
Blood marker study to predict severe bacterial lung infection
This study looks at specific immune cells and how fats are transported in the blood to predict which people will have a severe bacterial infection (like pneumonia or sepsis). Your results may help doctors identify higher-risk patients earlier.
MinskAges 18–60 - NCT06966284Recruiting
Study Comparing Two Antibiotics for Resistant Infections
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
TaipeiAges 18 years+ - NCT07206745Recruiting
Chinese and Western medicine for severe pneumonia from drug-resistant bacteria
This trial tests a combination of traditional Chinese and Western medicine for adults with severe pneumonia caused by bacteria that are resistant to multiple antibiotics. It aims to see if this combined approach can improve treatment outcomes.
Zhengzhou, HenanAges 18–80 - NCT06602557RecruitingPhase 2
Inhaled antibiotic for lung infection during ECMO support
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
ParisAges 18 years+ - NCT06162286RecruitingPhase 3
Comparing two antibiotics for pneumonia in adults
This trial tests a new antibiotic (omadacycline) compared to a standard one (moxifloxacin) for adults with community-acquired pneumonia. The goal is to see if the new drug is as safe and effective.
BeijingAges 18 years+ - NCT07406334RecruitingPhase 1
Pneumococcal booster vaccine study for toddlers
This trial tests a new pneumococcal vaccine as a booster shot in toddlers who already got a full primary series. It aims to see if the booster is safe and produces a strong immune response.
Soweto, Johannesburg, GautengAges 1 year–1.3 years - NCT07593547Recruiting
Combination vs. single drug for Stenotrophomonas infection
This study compares treating Stenotrophomonas maltophilia (a hospital-acquired bacterial infection) with two drugs together versus one drug alone. The goal is to see which approach works better and is safer for adult hospital patients.
Madrid, MadridAges 18 years+ - NCT06135350RecruitingPhase 2
Preventing infections in ICU patients on ventilators
This trial tests an experimental drug called Fluorothiazinone to prevent serious bacterial infections in ICU patients who are on a breathing machine (ventilator) or likely to need one soon. It includes patients with COVID-19 pneumonia, stroke, or heart failure.
Moscow, MoscowAges 18 years+ - NCT05922124RecruitingPhase 4
Testing two antibiotics against resistant lung and bloodstream infections
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
HaifaAges 16 years+ - NCT05117125Recruiting
Testing for markers in early ventilator lung infections
This study looks at changes (biomarkers) in the blood or other samples from people on a breathing machine. It may help doctors detect ventilator-associated pneumonia earlier and tailor treatment sooner.
DrammenAges 18 years+
Hear when a new Pneumonia, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pneumonia, bacterial?
- Yes. Clin2 currently lists 27 recruiting pneumonia, bacterial studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pneumonia, bacterial trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pneumonia, bacterial trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.